Natural killer cell functional dichotomy: A feature of chronic viral hepatitis?

Frontiers in Immunology

Volumn 3, Issue NOV, 2012, Pages

  Mondelli, Mario U ^a,b   Oliviero, Barbara ^a   Mele, Dalila ^a   Mantovani, Stefania ^a,b   Gazzabin, Chiara ^a   Varchetta, Stefania ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

HBV; HCV; IFN ; IFN ; Liver diseases

Indexed keywords

EID: 84874221998     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00351     Document Type: Short Survey

References (58)

1. Abel, M., Sene, D., Pol, S., Bourliere, M., Poynard, T., Charlotte, F., et al. (2006). Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 44, 1607-1616.
2. Accapezzato, D., Francavilla, V., Paroli, M., Casciaro, M., Chircu, L. V., Cividini, A., et al. (2004). Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J. Clin. Invest. 113,963-972.
3. Ahlenstiel, G., Edlich, B., Hog-dal, L. J., Rotman, Y., Noured-din, M., Feld, J. J., et al. (2011). Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 141, 1231-1239, 1239.el231-e1232.
4. Ahlenstiel, G., Titerence, R. H., Koh, C., Edlich, B., Feld, J. J., Rotman, Y., et al. (2010). Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138,325-335.e321-e322.
5. Biron, C. A. (1997). Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 9,24-34.
6. Bolanos, E D., and Tripathy, S. K. (2011). Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible. J. Immunol. 186, 2765-2771.
7. Bonorino, P., Ramzan, M., Camous, X., Dufeu-Duchesne, T., Thelu, M. A., Sturm, N., et al. (2009). Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J. Hepatol. 51,458-467.
8. Chen, Q., Carroll, H. P., and Gadina, M. (2006). The newest interleukins: recent additions to the ever-growing cytokine family. Vitam. Horm. 74, 207-228.
9. Crotta, S., Stilla, A., Wack, A., D'Andrea, A., Nuti, S., D'Oro, U., et al. (2002). Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.J. Exp. Med. 195, 35-41.
10. Davis, G. L., Albright, J. E., Cook, S. E, and Rosenberg, D. M. (2003). Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 9, 331-338.
11. de Lucas, S., Bartolome, J., and Carreno, V. (2005). Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J. Infect. Dis. 191,93-99.
12. De Maria, A., Bozzano, F., Can-toni, C., and Moretta, L. (2011). Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc. Natl. Acad. Sci. U.S.A. 108, 728-732.
13. Dessouki, O., Kamiya, Y., Nagahama, H., Tanaka, M., Suzu, S., Sasaki, Y., et al. (2010). Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment. Biochem. Biophys. Res. Commun. 393, 331-337.
14. de Weerd, N. A., Samarajiwa, S. A., and Hertzog, P. J. (2007). Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282,20053-20057.
15. Du, J., Liang, X., Liu, Y., Qu, Z., Gao, L., Han, L., et al. (2009). Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death. Differ 16,219-229.
16. Dunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P. T., Lampertico, P., et al. (2007). Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667-680.
17. Edlich, B., Ahlenstiel, G., Azpiroz, A. Z., Stoltzfus, J., Noureddin, M., Serti, E., et al. (2012). Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 55, 39-48.
18. European Association for the Study of the Liver. (2012). EASL clinical practice guidelines: management of chronic hepatatis B virus infection. J. Hepatol. 57, 167-185.
19. Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., et al. (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401.
20. Golden-Mason, L., Bambha, K. M., Cheng, L., Howell, C. D., Taylor, M. W., Clark, P. J., et al. (2011). Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 54, 1559-1569.
21. Golden-Mason, L., Madrigal-Estebas, L., Mcgrath, E., Conroy, M. J., Ryan, E. J., Hegarty, J. E., et al. (2008). Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57,1121- 1128.
22. Guidotti, L. G., and Chisari, E V. (2001). Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19,65-91.
23. Guidotti, L. G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., and Chisari, E V. (1999). Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-829.
24. Herzer, K., Falk, C. S., Encke, J., Eichhorst, S. T., Ulsenheimer, A., Seliger, B., et al. (2003). Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J. Virol. 77, 8299-8309.
25. Hoffmann, C. J., and Thio, C. L. (2007). Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect. Dis. 7, 402-409.
26. Ju, Y., Hou, N., Meng, J., Wang, X. Zhang, X., Zhao, D., et al. (2010). T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J. Hepatol. 52, 322-329.
27. Kotenko, S. V., Gallagher, G., Bau-rin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., et al. (2003). IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77.
28. Kramer, B., Korner, C., Kebschull, M., Glassner, A., Eisenhardt, M., Nischalke, H. D., et al. (2012). NKp46(High) expression defines a NK cell subset that is potentially involved in control of HCV replication and modulation of liver fibrosis. Hepatology 56, 1201-1213.
29. Lang, T., Lo, C., Skinner, N., Locarnini, S., Visvanathan, K., and Mansell, A. (2011). The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J. Hepatol. 55, 762-769.
30. Lassen, M. G., Lukens, J. R., Dolina, J. S., Brown, M. G., and Hahn, Y. S. (2010). Intrahepatic IL-10 maintains NKG2A+Ly49- liver NK cells in a functionally hyporesponsive state. J. Immunol. 184,2693-2701.
31. Liaw, Y E, and Chu, C. M. (2009). Hepatitis B virus infection. Lancet 373, 582-592.
32. Ma, J., Guo, X., Wu, X., Li, J., Zhu, X., Li, Z., et al. (2010). Association of NKG2D genetic polymorphism with susceptibility to chronic hepatitis B in a Han Chinese population. J. Med. Virol. 82, 1501-1507.
33. Meier, U. C., Owen, R. E., Taylor, E., Worth, A., Naoumov, N., Will-berg, C., et al. (2005). Shared alterations in NK cell frequency, pheno-type, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 79, 12365-12374.
34. Meurs, E. F., and Breiman, A. (2007). The interferon inducing pathways and the hepatitis C virus. World J. Gastroenterol. 13,2446-2454.
35. Miyagi, T., Takehara, T., Nishio, K., Shimizu, S., Kohga, K., Li, W., et al. (2010). Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J. Hepatol. 53, 424-430.
36. Morishima, C., Paschal, D. M., Wang, C. C., Yoshihara, C. S., Wood, B. L., Yeo, A. E., et al. (2006). Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43, 573-580.
37. Nattermann, J., Nischalke, H. D., Hofmeister, V., Ahlenstiel, G., Zim-mermann, H., Leifeld, L., et al. (2005). The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am. J. Pathol. 166, 443-453.
38. Oliviero, B., Varchetta, S., Paudice, E., Michelone, G., Zaramella, M., Mavilio, D., et al. (2009). Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137, 1151-1160, 1160.e1151-e1157.
39. Peppa, D., Micco, L., Javaid, A., Kennedy, P. T., Schurich, A., Dunn, C., et al. (2010). Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 6, e1001227. doi: 10.1371/journal.ppat.1001227
40. Raimondo, G., Allain, J. P., Brunetto, M. R., Buendia, M. A., Chen, D. S., Colombo, M., et al. (2008). Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49, 652-657.
41. Rehermann, B., and Nascimbeni, M. (2005). Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215-229.
42. Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., et al. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63-68.
43. Shi, C. C., Tjwa, E. T., Biesta, P. J., Boon-stra, A., Xie, Q., Janssen, H. L., et al. (2012a). Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells. J. Viral. Hepat. 19
44. Shi, K. Q., Cai, X. H., Xiao, D. D., Wu, S. J., Peng, M. M., Lin, X. E, et al. (2012b). Tumour necrosis factor-alpha-857T allele reduces the risk of hepatitis B virus infection in an Asian population. J. Viral. Hepat. 19,e66-e72.
45. Stegmann, K. A., Bjorkstrom, N. K., Veber, H., Ciesek, S., Riese, P., Wie-gand, J., et al. (2010). Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138, 1885-1897.
46. Sun, C., Fu, B., Gao, Y., Liao, X., Sun, R., Tian, Z., et al. (2012). TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog. 8, e1002594. doi: 10.1371/journal.ppat.1002594
47. Suppiah, V., Gaudieri, S., Armstrong, N. J., O'Connor, K. S., Berg, T., Weltman, M., et al. (2011). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med. 8, e1001092. doi: 10.1371/journal.pmed.1001092
48. Thein, H. H., Yi, Q., Dore, G. J., and Krahn, M. D. (2008). Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48, 418-431.
49. Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O'Huigin, C., et al. (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801.
50. Tjwa, E. T., Van Oord, G. W., Hegmans, J. P., Janssen, H. L., and Woltman, A. M. (2011). Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J. Hepatol. 54, 209-218.
51. Tripathy, S. K., Keyel, P. A., Yang, L., Pin-gel, J. T., Cheng, T. P., Schneeberger, A., et al. (2008). Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J. Exp. Med. 205, 1829-1841.
52. Tseng, C. T., and Klimpel, G. R. (2002). Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195,43-49.
53. Varchetta, S., Mele, D., Mantovani, S., Oliviero, B., Cremonesi, E., Ludovisi, S., et al. (2012). Impaired intrahepatic natural killer cell cyto-toxic function in chronic hepatitis C virus infection. Hepatology 56, 841-849.
54. Wei, C., Ni, C., Song, T., Liu, Y., Yang, X., Zheng, Z., et al. (2010). The hepatitis B virus X protein disrupts innate immunity by downregulating mito-chondrial antiviral signaling protein. J. Immunol. 185, 1158-1168.
55. Wieland, S. F., and Chisari, E V (2005). Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 79, 9369-9380.
56. Woltman, A. M., Op Den Brouw, M. L., Biesta, P. J., Shi, C. C., and Janssen, H. L. (2011). Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 6, e15324. doi: 10.1371/jour-nal.pone.0015324
57. Zhang, Z., Zhang, S., Zou, Z., Shi, J., Zhao, J., Fan, R., et al. (2011). Hyper-cytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53, 73-85.
58. Zheng, M. H., Xiao, D. D., Lin, X. F., Wu, S. J., Peng, M. M., Yu, X. Y., et al. (2012). The tumour necrosis factor-alpha-238A allele increases the risk of chronic HBV infectionin Euro-pean populations. J. Viral Hepat. 19, e11-e17.